YARDLEY, PA, December 17, 2015 — OptiNose today announced that the company will present at the 34th annual J.P. Morgan Healthcare Conference. CEO Peter Miller will discuss the Company’s recent milestones, pipeline and strategy for 2016.
“Our Bi-Directional Breath Powered platform technology has proven to be a great basis for development of multiple products. Clinical development efforts with our Exhalers in 2015 have produced great results and our company is in an increasingly strong position to grow value in 2016,” Miller stated. “We look forward to providing the investment community an update on our business, including our exciting pipeline, our strategic options and the products we will be advancing to the next stage in 2016 and beyond.”
Miller will present on Monday, January 11, 2016 at 4:30 p.m. in the Elizabethan C/D room at the Westin St. Francis Hotel in San Francisco.
Background Information
About OptiNose Technology: Bi-Directional™ Breath Powered™ Drug Delivery Systems
OptiNose’s patented technology for closed-palate Bi-Directional Breath Powered drug delivery systems is unique in that its exhalation devices use the natural functions of a patient’s breath to help effectively and efficiently deliver medications beyond the nasal valve into deep, targeted areas of the nasal cavity. A user exhales into the device, naturally closing the soft palate and sealing off the nasal cavity from the throat. The exhaled breath carries medication from the device into one side of the nose through a specially shaped sealing nosepiece, balancing the pressure on the soft palate. Narrow nasal passages are gently expanded and medication is transported well beyond the nasal valve to targeted sites. After delivering medication to the targeted sites, air flows around to the opposite side of the nasal cavity and exits through the other side of the nose rather than into the throat or lungs.
About OptiNose
OptiNose is a Specialty Biopharmaceutical Company developing a promising pipeline of late stage new products. The Company’s patented closed-palate Bi-Directional™ Breath Powered™ drug delivery systems enable differentiated treatments using exhaler devices that serve to target delivery of drugs high and deep in the nose. OptiNose successfully out-licensed a first product at the end of phase 3 (AVP-825 for Migraine, licensed to Avanir in North America, since purchased by Otsuka Pharmaceutical Co., Ltd.), and has reported clinical success with other products, including OPN-375, a treatment in development for Chronic Nasal Inflammatory Diseases (CNID). Other OptiNose pipeline products also target large markets with significant unmet need, including “nose-to-brain” applications of the technology such as OPN-300 for Autism. OptiNose has corporate offices in the US, Norway and the UK. For more information, please visit www.optinose.com.
Investors in OptiNose include Avista Capital Partners in New York, WFD Ventures LLC located in New York and Entrepreneurs Fund LP based in Jersey, Channel Islands.
Forward Looking Statements
This press release may contain forward looking statements. Forward looking statements include statements about our future plans and may be indicated by words such as, “we expect,” “we plan,” or other similar words. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. We are not obligating ourselves to revise or publicly release the results of any revision to these forward looking statements in light of new information or future events.
OptiNose Media Contact
Kate Traynor, Sloane & Company
Ktraynor@sloanepr.com
212.446.1871